TaxTMI Login
Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
of 
of 
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of of 
All News
of of All News
Note
Bookmark
Share
Don't have an account? Register Here
of <h1>Servier India Introduces Ivosidenib: Targeted Therapy Breakthrough for IDH1 Mutation in Rare Cancer Treatment</h1> Servier India launched Ivosidenib, a targeted therapy for Acute Myeloid Leukemia and Cholangiocarcinoma with IDH1 mutation. The medication received regulatory approval in May 2025, addressing critical treatment gaps for rare cancers. The pharmaceutical company aims to improve patient outcomes by providing innovative, accessible treatment options, focusing on precision medicine and enhancing cancer care in India.
TaxTMI 
TaxTMI 
